Articles

Vote would let big conferences set their own rules

The NCAA board of directors will vote Thursday on a proposal that would give the five wealthiest college football conferences the ability to make rules and pass legislation without the approval of the rest of Division I schools.

Read More

WellPoint unit launching $80M information exchange

Two insurers announced Tuesday that they are partnering for an ambitious project to establish one of the nation's largest health-information exchanges, an effort they hope will reduce duplication and improve patient outcomes.

Read More

FDA approves Lilly, Boehringer diabetes drug

The Food and Drug Administration said Friday it will permit Jardiance tablets to be used by adult patients with type 2 diabetes who also are trying to control their condition with diet and exercise.

Read More

NCAA settles head injury suit, will change rules

In a deal expected to “change college sports forever,” the NCAA agreed Tuesday to settle a class-action head injury lawsuit by creating a $70 million fund to diagnose thousands of current and former college athletes to determine if they suffered brain trauma.

Read More

Deal worth $17B aimed at improving veteran health care

The bipartisan agreement includes $10 billion in to make it easier for veterans who can’t get prompt appointments with Veterans Affairs doctors to obtain outside care; $5 billion to hire doctors, nurses and other medical staff; and about $1.5 billion to lease 27 new clinics across the country.

Read More

Most drug money in Indiana funds research. Is that good?

With federal research funding declining, drug companies are taking a larger role funding the medical research happening at IU and universities around the country. That’s not the same thing as paying to market drugs, but it’s hardly without controversy.

Read More

Roche drug trial backs Lilly on Alzheimer’s findings

Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.

Read More